Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

about

Adolescent perspectives on the return of individual results in genomic addiction research.Practices and views of neurologists regarding the use of whole-genome sequencing in clinical settings: a web-based survey.

P2860

Q37391158-EDA16C13-81BB-4E62-87F9-876F82EDE347 Q38685738-2A34F6FB-6542-4FD0-A616-849CC6A49093

P2860

Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

Item

http://www.wikidata.org/entity/Q38097535

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Disclosure of individual pharm ...... turn to research participants.

@en

type

Item

label

Disclosure of individual pharm ...... turn to research participants.

@en

prefLabel

Disclosure of individual pharm ...... turn to research participants.

@en

P1476

Disclosure of individual pharm ...... turn to research participants.

@en

P2093

Béatrice Godard

http://www.w3.org/2001/XMLSchema#string

Sandra Korol

http://www.w3.org/2001/XMLSchema#string

Simon de Denus

http://www.w3.org/2001/XMLSchema#string

Thierry Hurlimann

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

Genomics really gets personal: how exome and whole genome sequencing challenge the ethical framework of human genetics research

Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study.

Pharmacogenomics: translating functional genomics into rational therapeutics.

Disclosure of individual genetic data to research participants: the debate reconsidered.

Personal genome research : what should the participant be told?

Tailoring the process of informed consent in genetic and genomic research

Incidental findings in data-intensive postgenomics science and legal liability of clinician-researchers: ready for vaccinomics?

2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Associa

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

P304

675-688

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.13.50

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23570470

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

about

P2860

P2860

Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921